These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene. Tonini G; Bizzarri C; Bonfanti R; Vanelli M; Cerutti F; Faleschini E; Meschi F; Prisco F; Ciacco E; Cappa M; Torelli C; Cauvin V; Tumini S; Iafusco D; Barbetti F; Diabetologia; 2006 Sep; 49(9):2210-3. PubMed ID: 16816952 [No Abstract] [Full Text] [Related]
4. [Regadrin treatment of diabetes mellitus]. Hohlfeld R; Neugebauer A; Haaser B; Marek H; Reuter W Z Gesamte Inn Med; 1973 May; 28(10):Suppl 10:154-6. PubMed ID: 4734038 [No Abstract] [Full Text] [Related]
5. Glucose tolerance, plasma insulin and lipids in diabetic subjects before and after treatment with a new sulfonylurea compounds, Ro 6-4563. Berchtold P; Björntorp P; Gustafson A; Jonsson A; Fagerberg SE Eur J Clin Pharmacol; 1971 Dec; 4(1):22-8. PubMed ID: 5151389 [No Abstract] [Full Text] [Related]
6. [25 years of diabetic treatment by oral hypoglycemic agents: successes and failures]. Tattersall RB Journ Annu Diabetol Hotel Dieu; 1984; ():183-91. PubMed ID: 6443219 [No Abstract] [Full Text] [Related]
8. Update on diabetes mellitus. Moss JM Med Times; 1981 Aug; 109(8):70-3. PubMed ID: 7024704 [No Abstract] [Full Text] [Related]
9. Clinical evaluation of glibornuride (glutril): a new oral antidiabetic drug. van der Merwe M; van Rooyen R S Afr Med J; 1973 Sep; 47(36):1638-42. PubMed ID: 4746966 [No Abstract] [Full Text] [Related]
15. [Medium term effect (3 months) of hypoglycemic sulfamide treatment (gliclazide) on insulin secretion of the non-insulin dependent diabetic]. Brogard JM; Pinget M; Leconte A; Dorner M Rev Med Interne; 1982 Dec; 3(4):379-87. PubMed ID: 6761818 [No Abstract] [Full Text] [Related]
16. [The therapeutic value of combined treatment with biguanides and sulfonylurea preparations in the presence of resistance to sulfanilamide drugs in diabetes mellitus patients]. Penchev I; Andreev D; Popov A; Pampulov L Probl Endokrinol (Mosk); 1970; 16(6):3-7. PubMed ID: 5521087 [No Abstract] [Full Text] [Related]
17. Modifications of glycemia and insulinemia in diabetics treated with glipizide (K 4024), a new sulfonylurea. Fedele D; Tiengo A; Riva F; Muggeo M; Emanueli A; Crepaldi G Arzneimittelforschung; 1972 Nov; 22(11):1885-8. PubMed ID: 4679060 [No Abstract] [Full Text] [Related]
18. [Content of immunoreactive insulin in the plasma and insulin sensitivity in patients with diabetes mellitus during the process of sulfanilamide compensation of metabolic disorders]. Bogatyreva ShI; Dzeranova NIa; Shlimovich PB Probl Endokrinol (Mosk); 1972; 18(3):22-5. PubMed ID: 5029279 [No Abstract] [Full Text] [Related]
19. Clinical comparison between glipentide (Staticum) and glibenclamide in diabetics. Moncada Lorenzo E; Garcia RV; Barberia Layana JJ; Morant Ciscard JA; Calleja Canelas A Curr Ther Res Clin Exp; 1977 Jan; 21(1):50-7. PubMed ID: 401712 [No Abstract] [Full Text] [Related]
20. A controlled clinical trial of a new oral hypoglycemic agent, glipizide (K 4024). Lentini S; Bossini A; Pirola LC Arzneimittelforschung; 1972 Jul; 22(7):1169-73. PubMed ID: 4678124 [No Abstract] [Full Text] [Related] [Next] [New Search]